“These data are an important advancement in our obesity portfolio because they increase significantly our confidence in the phase three monthly dosing study that we expect to start later this year.”

In context

“pment, regulatory, and medical to increase productivity and accelerate the pipeline and timelines. AI is optimizing supply planning and manufacturing, contributing to our manufacturing optimization program goals. In commercial, AI is helping to accelerate new product launches, delivering insights for dynamic targeting, and supporting personalized messaging and real-time marketing content. So with that and after I described the four priorities, which describe the full picture of what you plan to do in 2026, I will turn it over to Chris to discuss the news of the day, which are the Metaira long-acting announcement of Vespar three. Chris. Chris Boshoff: Thank you, Albert. It is my pleasure to discuss the VSPR three study results today and provide more color to our press release this morning. These data are an important advancement in our obesity portfolio because they increase significantly our confidence in the phase three monthly dosing study that we expect to start later this year. To start, I'd like to review how the structure of PF-3944 drives its long half-life. Prior GLP-1 receptor agonists that rely on albumin binding to extend half-life require dissociation from the albumin protein for optimal receptor engagement. 3944 binds the GLP-1 receptor while still bound to albumin due to lipidation at the terminal end of the amino acid chain rather than the middle. This allows for reduced clearance without reduced receptor engagement, resulting in a half-life exceeding other agents that require albumin dissociation for binding. A key differentiator of 3944 is its extended half-life, which supports monthly dosing. Furthermore, given 3944's length of 41 amino acids, the molecule is considered a biologic and would be eligible for regulatory review by the BLA pathway. The”